Sees FY26 net income expected to exceed $230M; FY26 adjusted EBITDA expected to exceed $300M Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on ADMA: Adma Biologics sees FY25 revenue $485M, consensus $486.79M Adma Biologics announces partial paydown of senior term loan credit facility ADMA Biologics Announces Board Resignations and Appointments
